Cited 0 time in
Unexplained pancytopenia in a patient with 5q35.2-q35.3 microduplication encompassing nsd1: A case report
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Park, S. | - |
| dc.contributor.author | Lee, G.-W. | - |
| dc.contributor.author | Koh, E.-H. | - |
| dc.contributor.author | Kim, H.-Y. | - |
| dc.date.accessioned | 2022-12-26T18:16:57Z | - |
| dc.date.available | 2022-12-26T18:16:57Z | - |
| dc.date.issued | 2018 | - |
| dc.identifier.issn | 1735-1243 | - |
| dc.identifier.issn | 2008-2207 | - |
| dc.identifier.uri | https://scholarworks.gnu.ac.kr/handle/sw.gnu/13129 | - |
| dc.description.abstract | The 5q35.2-q35.3 duplication phenotype is characterized by growth delay, microcephaly, mental retardation and delayed bone aging. However, there has been no reports on the occurrence of pancytopenia as a consequence of 5q35.2-q35.3 duplication. A 42-year-old male visited the emergency room due to multiple trauma. He had been diagnosed with mental retardation in the past. Physical examination was unremarkable except for tenderness over bone fracture. Complete blood cell counts were leukocyte 3.51×109/L, neutrophil 0.19×109/L, hemoglobin 8.3 g/dL, hematocrit 25.0%, and platelet 4.0×109/L. There was no relevant history of any medication intake and there were no other haematological parameters leading to the persistent pancytopenia. A bone marrow biopsy revealed hypercellular marrow with increased trilineage hematopoiesis. The uptake of fluorodeoxyglucose was increased in multiple lymph nodes, bone and spleen in positron emission tomography? computed tomography. A biopsy of the right axillary lymph node was performed and histologic findings were unremarkable. The chromosomal microarray revealed a 3.46 Mb microduplication at the 5q35.2-q35.3 site including NSD1. The patient had distinctive features related to atypical pancytopenia. Various managements for pancytopenia had no effect on the patient. However, there were no complications such as massive bleeding or serious infection compared to the severity of pancytopenia during a follow-up of 3 months. In addition, periodic patterns of deterioration and improvement in pancytopenia appeared spontaneously. Since it is rare for these distinctive features of pancytopenia and chromosomal abnormality to coexist, it is important to investigate the association. In the current study, we describe the first case of 5q35.2-q35.3 microduplication encompassing NSD1 with unexplained pancytopenia. ? 2018, Tehran University of Medical Sciences (TUMS). All rights reserved. | - |
| dc.format.extent | 5 | - |
| dc.language | 영어 | - |
| dc.language.iso | ENG | - |
| dc.publisher | Tehran University of Medical Sciences (TUMS) | - |
| dc.title | Unexplained pancytopenia in a patient with 5q35.2-q35.3 microduplication encompassing nsd1: A case report | - |
| dc.type | Article | - |
| dc.publisher.location | 이란 | - |
| dc.identifier.doi | 10.18502/ijhoscr.v12i4.103 | - |
| dc.identifier.scopusid | 2-s2.0-85054752901 | - |
| dc.identifier.bibliographicCitation | International Journal of Hematology-Oncology and Stem Cell Research, v.12, no.4, pp 259 - 263 | - |
| dc.citation.title | International Journal of Hematology-Oncology and Stem Cell Research | - |
| dc.citation.volume | 12 | - |
| dc.citation.number | 4 | - |
| dc.citation.startPage | 259 | - |
| dc.citation.endPage | 263 | - |
| dc.type.docType | Article | - |
| dc.description.isOpenAccess | Y | - |
| dc.description.journalRegisteredClass | scopus | - |
| dc.subject.keywordAuthor | Chromosomal abnormality | - |
| dc.subject.keywordAuthor | Microarray | - |
| dc.subject.keywordAuthor | Pancytopenia | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
Gyeongsang National University Central Library, 501, Jinju-daero, Jinju-si, Gyeongsangnam-do, 52828, Republic of Korea+82-55-772-0532
COPYRIGHT 2022 GYEONGSANG NATIONAL UNIVERSITY LIBRARY. ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.
